Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655

Brain Research Bulletin

Volumn 55, Issue 3, 2001, Pages 387-391

  Szabados, Tamás ^a   Gigler, Gábor ^a   Gacsályi, István ^a   Gyertyán, István ^a   Lévay, György ^a  

^a EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

Audiogenic seizure; DBA 2j mice; Global cerebral ischaemia; GYKI 52466; Maximal electroshock; MgCl2

Indexed keywords

1 (4 AMINOPHENYL) 3 ACETYL 4 METHYL 3,4 DIHYDRO 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 (4 AMINOPHENYL) 3,4 DIHYDRO 4 METHYL 3 METHYLCARBAMOYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; BENZODIAZEPINE DERIVATIVE; GYKI 53405; MAGNESIUM CHLORIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN ISCHEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFECT; ELECTRIC SHOCK; ENZYME REPRESSION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SEIZURE; SURVIVAL TIME; TONIC CLONIC SEIZURE; TREATMENT OUTCOME;

ACOUSTIC STIMULATION; ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; BENZODIAZEPINES; BRAIN ISCHEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; MAGNESIUM CHLORIDE; MALE; MICE; MICE, INBRED STRAINS; NEUROPROTECTIVE AGENTS; SEIZURES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0034899184     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(01)00516-0     Document Type: Article

References (24)

1. Synergistic interactions between piracetam and dihydroergocristine in some animal model of cerebral hypoxia and ischaemia
2. Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: Stereospecificity and selectivity profiles
3. Pretreatment but not posttreatment with GYKI-52466 reduces functional deficits and neuronal damage after global ischaemia in rats
4. Investigations of non-NMDA receptor-induced toxicity in serum-free antioxidant-rich primary cultures of murine cerebellar granule cells
5. The anticonvulsant effect of the non-NMDA antagonists, NBQX and GYKI 52466, in mice
6. 2 receptor antagonist (s)-emopamil in cerebral ischaemia
7. Anticonvulsant actions of DS 103-282
8. GYKI 52466 and related 2,3-benzodiazepines as anticonvulsant agents in DBA/2 mice
9. Effect of a glutamate receptor antagonist (GYKI 52466) on 4-aminopyridine-induced seizure activity developed in rat cortical slices
10. GYKI 52466, a 2,3-benzodiazepine, is a highly selective, non-competitive antagonist of AMPA/kainate receptor responses
11. Non-N-methyl-D-aspartate receptor antagonism by 3-N-substituted 2,3-benzodiazepines: Relationship to anticonvulsant activity
12. The neuroprotective and hypothermic effect of GYKI-52466, a non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-antagonist on histological and behavioural variables in the gerbil global ischaemia model
13. AMPA receptor mediated excitotoxicity in neocortical neurons is developmentally regulated and dependent upon receptor desensitization
14. In vitro and in vivo effects of some non-competitive AMPA antagonist 2,3-benzodiazepines (GYKI-52466-HCl, 53405, 53655)
15. A simplified method of evaluating dose-effect experiments
16. Stereoselective effects of 2,3-benzodiazepines in vivo: Electrophysiology and neuroprotection studies
17. Effects of the non-NMDA antagonists NBQX and the 2,3-benzodiazepine GYKI 52466 on different seizure types in mice: Comparison with diazepam and interactions with flumazenil
18. 2+ channels
19. Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischaemia in the rat
20. Comparative assays of antiepileptic drugs in mice and rats
21. Effect of glutamate receptor antagonists on excitatory postsynaptic potentials in striatum
22. 2,3-Benzodiazepines (GYKI 52466 and analogs): Negative allosteric modulators of AMPA receptors
23. Pharmacological approaches to the study of brain hypoxia
24. Anticonvulsant activity of AMPA/kainate antagonists: Comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant seizure models